IgAN is a rare autoimmune disease mostly affecting young adults, which can lead to kidney failure. The study is to continue for a further 15 months. In total, it will cover around 450 adult patients with primary IgAN who are at high risk of progressing to kidney failure.
from Top Health News | Latest Healthcare Sector & Healthcare Industry news, Information and Updates: ET HealthWorld : ETHealthworld.com https://ift.tt/14pvaWU
Home »
Information and Updates: ET HealthWorld : ETHealthworld.com
,
Top Health News | Latest Healthcare Sector & Healthcare Industry news
» Novartis says positive interim results on rare kidney disease drug
https://ift.tt/8xpgiPs
No comments:
Post a Comment